Candel Therapeutics, Inc. financial data

Symbol
CADL on Nasdaq
Location
117 Kendrick Street, Suite 450, Needham, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 364 % +43.7%
Debt-to-equity 52.9 % -85.7%
Return On Equity -41 % +93.5%
Return On Assets -26.8 % +80%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 54.9M shares +71.1%
Common Stock, Shares, Outstanding 54.9M shares +76.7%
Entity Public Float 163M USD +478%
Common Stock, Value, Issued 549K USD +81.2%
Weighted Average Number of Shares Outstanding, Basic 51.5M shares +72.3%
Weighted Average Number of Shares Outstanding, Diluted 51.5M shares +72.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 21.2M USD -4.26%
General and Administrative Expense 15M USD +11.1%
Operating Income (Loss) -36.2M USD -1.55%
Nonoperating Income (Expense) 14.1M USD
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -22.1M USD +55.7%
Earnings Per Share, Basic 0 USD/shares +61.2%
Earnings Per Share, Diluted 0 USD/shares +60%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 101M USD +369%
Assets, Current 104M USD +356%
Property, Plant and Equipment, Net 1.66M USD -39%
Operating Lease, Right-of-Use Asset 391K USD -42.8%
Assets 106M USD +300%
Accounts Payable, Current 1.95M USD +351%
Employee-related Liabilities, Current 1.93M USD -4.35%
Accrued Liabilities, Current 4.32M USD +34.3%
Liabilities, Current 14.7M USD +5.14%
Operating Lease, Liability, Noncurrent 104K USD -85.1%
Liabilities 15.8M USD -56.8%
Retained Earnings (Accumulated Deficit) -190M USD -13.2%
Stockholders' Equity Attributable to Parent 90.2M USD
Liabilities and Equity 106M USD +300%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -8.62M USD -2.11%
Net Cash Provided by (Used in) Financing Activities -1.87M USD -49%
Net Cash Provided by (Used in) Investing Activities -3K USD +57.1%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 55M shares +76.4%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -10.5M USD -8.13%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 101M USD +365%
Interest Paid, Excluding Capitalized Interest, Operating Activities 252K USD -54.1%
Deferred Tax Assets, Valuation Allowance 52.2M USD +28.7%
Deferred Tax Assets, Gross 52.5M USD +27.8%
Operating Lease, Liability 698K USD -43.6%
Depreciation 984K USD +0.31%
Payments to Acquire Property, Plant, and Equipment 3K USD -57.1%
Lessee, Operating Lease, Liability, to be Paid 724K USD -45.5%
Property, Plant and Equipment, Gross 5.22M USD -1.73%
Operating Lease, Liability, Current 594K USD +10.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 415K USD -32.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 415K USD -32.3%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 26K USD -71.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 415K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 29.9M USD +29.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Operating Lease, Payments 702K USD +19.6%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 230K USD +39.4%
Deferred Tax Assets, Net of Valuation Allowance 277K USD -44.7%
Share-based Payment Arrangement, Expense 3.79M USD -15.9%
Interest Expense -2.76M USD -4.78%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%